• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
SAR Study of 4,8-Disubstituted Pyrimido[5,4-]pyrimidines Exhibiting Antitrypanosomal and Antileishmanial Activity.具有抗锥虫和抗利什曼原虫活性的4,8-二取代嘧啶并[5,4-]嘧啶的构效关系研究。
ACS Med Chem Lett. 2024 Aug 22;15(9):1541-1548. doi: 10.1021/acsmedchemlett.4c00277. eCollection 2024 Sep 12.
2
PubChem BioAssays 1063: A Poorly Exploited Source of New Antileishmanial Compounds.《公共化学数据库生物测定1063:新型抗利什曼原虫化合物的未充分利用来源》
J Parasitol Res. 2025 Jun 27;2025:6338486. doi: 10.1155/japr/6338486. eCollection 2025.
3
Pyrimido[5,4-]pyrimidine-Based Compounds as a Novel Class of Antitrypanosomal and Antileishmanial Agents.基于嘧啶并[5,4-]嘧啶的化合物作为一类新型抗锥虫和抗利什曼原虫药物。
ACS Med Chem Lett. 2022 Aug 9;13(9):1427-1433. doi: 10.1021/acsmedchemlett.2c00170. eCollection 2022 Sep 8.
4
Novel pyrazole carboxylate derivatives as lonazolac bioisosteres with selective COX-2 inhibition: design, synthesis and anti-inflammatory activity.新型吡唑羧酸酯衍生物作为洛那唑酸生物电子等排体具有选择性COX-2抑制作用:设计、合成及抗炎活性
Mol Divers. 2025 May 22. doi: 10.1007/s11030-025-11220-8.
5
In Vitro and In Silico Assessments of Curcuminoids and Turmerones from as Novel Inhibitors of Arginase.姜黄素类化合物和姜黄酮作为精氨酸酶新型抑制剂的体外和计算机模拟评估
Pharmaceuticals (Basel). 2025 Jun 6;18(6):851. doi: 10.3390/ph18060851.
6
A Systematic Review of Curcumin and its Derivatives as Valuable Sources of Antileishmanial Agents.姜黄素及其衍生物作为抗利什曼原虫药物的有价值来源的系统评价。
Acta Parasitol. 2021 Sep;66(3):797-811. doi: 10.1007/s11686-021-00351-1. Epub 2021 Mar 26.
7
Antiparasitic Activities of Plants From the Traditional Senegalese Pharmacopoeia: Isolation of Antitrypanosomal and Antileishmanial Ellagic Acid Derivatives From Terminalia Avicennioides.塞内加尔传统药典中植物的抗寄生虫活性:从阿江榄仁中分离抗锥虫和抗利什曼原虫的鞣花酸衍生物
Chem Biodivers. 2025 Jun;22(6):e202403320. doi: 10.1002/cbdv.202403320. Epub 2025 Jan 28.
8
Interventions for Old World cutaneous leishmaniasis.旧世界皮肤利什曼病的干预措施。
Cochrane Database Syst Rev. 2017 Dec 1;12(12):CD005067. doi: 10.1002/14651858.CD005067.pub5.
9
Interventions for Old World cutaneous leishmaniasis.旧世界皮肤利什曼病的干预措施。
Cochrane Database Syst Rev. 2017 Nov 17;11(11):CD005067. doi: 10.1002/14651858.CD005067.pub4.
10
Characterizing Leishmania infantum-induced resistance to trivalent stibogluconate (SbIII) through deep proteomics.通过深度蛋白质组学研究鉴定利什曼原虫诱导的三价葡萄糖酸锑(SbIII)耐药性。
J Proteomics. 2024 Oct 30;309:105323. doi: 10.1016/j.jprot.2024.105323. Epub 2024 Sep 28.

引用本文的文献

1
Synthesis of Tricyclic and Tetracyclic Lactone Derivatives of Thieno[2,3-]pyrazine or Thieno[2,3-]quinoline: Preliminary Antitumor and Antiparasitic Activity Evaluation.噻吩并[2,3 - ]吡嗪或噻吩并[2,3 - ]喹啉的三环和四环内酯衍生物的合成:初步抗肿瘤和抗寄生虫活性评估
Molecules. 2025 Apr 30;30(9):1999. doi: 10.3390/molecules30091999.

本文引用的文献

1
Synthetic product-based approach toward potential antileishmanial drug development.基于合成产物的潜在抗利什曼病药物开发方法。
Eur J Med Chem. 2024 Jan 5;263:115927. doi: 10.1016/j.ejmech.2023.115927. Epub 2023 Nov 11.
2
Pyrimido[5,4-]pyrimidine-Based Compounds as a Novel Class of Antitrypanosomal and Antileishmanial Agents.基于嘧啶并[5,4-]嘧啶的化合物作为一类新型抗锥虫和抗利什曼原虫药物。
ACS Med Chem Lett. 2022 Aug 9;13(9):1427-1433. doi: 10.1021/acsmedchemlett.2c00170. eCollection 2022 Sep 8.
3
Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study.口服非昔硝唑治疗 1 期或早期 2 期冈比亚布氏锥虫非洲锥虫病:一项前瞻性、多中心、开放性、队列研究。
Lancet Glob Health. 2021 Jul;9(7):e999-e1008. doi: 10.1016/S2214-109X(21)00208-4.
4
Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives.内脏利什曼病治疗的最新进展:成功、陷阱和展望。
Clin Microbiol Rev. 2018 Aug 29;31(4). doi: 10.1128/CMR.00048-18. Print 2018 Oct.
5
Leishmaniasis.利什曼病。
Lancet. 2018 Sep 15;392(10151):951-970. doi: 10.1016/S0140-6736(18)31204-2. Epub 2018 Aug 17.
6
Human African trypanosomiasis.非洲人类锥虫病。
Lancet. 2017 Nov 25;390(10110):2397-2409. doi: 10.1016/S0140-6736(17)31510-6. Epub 2017 Jun 30.
7
Control of the leishmaniases.利什曼病的控制
World Health Organ Tech Rep Ser. 2010(949):xii-xiii, 1-186, back cover.
8
Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management.米替福新治疗利什曼病:知情临床风险管理的临床证据。
Ther Clin Risk Manag. 2007 Oct;3(5):733-40.
9
Paromomycin in the treatment of leishmaniasis.巴龙霉素治疗利什曼病
Expert Opin Investig Drugs. 2008 May;17(5):787-94. doi: 10.1517/13543784.17.5.787.
10
Amphotericin biosynthesis in Streptomyces nodosus: deductions from analysis of polyketide synthase and late genes.诺卡氏链霉菌中两性霉素的生物合成:基于聚酮合酶和晚期基因分析的推断
Chem Biol. 2001 Jul;8(7):713-23. doi: 10.1016/s1074-5521(01)00046-1.

具有抗锥虫和抗利什曼原虫活性的4,8-二取代嘧啶并[5,4-]嘧啶的构效关系研究。

SAR Study of 4,8-Disubstituted Pyrimido[5,4-]pyrimidines Exhibiting Antitrypanosomal and Antileishmanial Activity.

作者信息

Lopes André, Teixeira Sofia, Santarém Nuno, Greco Alessandro, Pagliaro Angela, Keminer Oliver, Gul Sheraz, Cordeiro-da-Silva Anabela, Carvalho Maria Alice

机构信息

Centre of Chemistry of University of Minho (CQUM), Campus de Gualtar, Braga, Portugal and Departamento de Química, Escola de Ciências da Universidade do Minho, Braga 4710-057, Portugal.

Instituto de Investigação e Inovação em Saúde, Universidade do Porto and Institute for Molecular and Cell Biology, University of Porto, Porto 4150-180, Portugal.

出版信息

ACS Med Chem Lett. 2024 Aug 22;15(9):1541-1548. doi: 10.1021/acsmedchemlett.4c00277. eCollection 2024 Sep 12.

DOI:10.1021/acsmedchemlett.4c00277
PMID:39291018
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11403736/
Abstract

A set of new derivatives of 4,8-disubstituted pyrimido[5,4-]pyrimidines were efficiently synthesized and evaluated against and promastigotes and intramacrophage amastigotes. The cytotoxicity was determined using the THP-1 cell line, and early ADME-Tox was carried out using assays for cytotoxicity (A549 and HEK293 cell lines) and CYP3A4 and hERG cardiotoxicity liabilities. All the new compounds were active against (0.11 μM ≤ IC ≤ 8.72 μM; 1 ≤ selectivity index (SI) ≤ 877), but only eight were active against promastigotes (0.20 μM ≤ IC ≤ 14.88 μM; 1 ≤ SI < 502) with three also active against intramacrophage amastigotes (3.00 μM ≤ IC ≤ 8.51 μM). Compounds , , and were identified as the hit compounds to further develop as antitrypanosomal and antileishmanial agents.

摘要

高效合成了一组4,8-二取代嘧啶并[5,4 -]嘧啶的新衍生物,并对其抗前鞭毛体和巨噬细胞内无鞭毛体的活性进行了评估。使用THP - 1细胞系测定细胞毒性,并使用细胞毒性测定法(A549和HEK293细胞系)以及CYP3A4和hERG心脏毒性评估方法进行早期药物代谢动力学 - 毒性(ADME - Tox)研究。所有新化合物对(0.11 μM≤IC≤8.72 μM;1≤选择性指数(SI)≤877)均有活性,但只有八种对前鞭毛体有活性(0.20 μM≤IC≤14.88 μM;1≤SI < 502),其中三种对巨噬细胞内无鞭毛体也有活性(3.00 μM≤IC≤8.51 μM)。化合物、和被确定为有潜力进一步开发为抗锥虫和抗利什曼原虫药物的活性化合物。